Restricted accessResearch articleFirst published online 2020-5
Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials
Sarcosine (N-methylglycine), a type 1 glycine transporter inhibitor (GlyT1), has shown therapeutic potential for treating schizophrenia; however, studies have reported conflicting results. This meta-analysis aimed to explore the efficacy and cognitive effect of sarcosine for schizophrenia.
Methods:
In this study, PubMed, Cochrane Systematic Reviews, and Cochrane Collaboration Central Register of Controlled Clinical Trials were searched electronically for double-blinded randomised controlled trials that used sarcosine for treating schizophrenia. We used the published trials up to November 2019 to investigate the efficacy of sarcosine in schizophrenia. We pooled studies by using a random-effect model for comparing sarcosine treatment effects. Patients who were diagnosed with schizophrenia according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition were recruited. Clinical improvement and cognitive function scores between baseline and after sarcosine use were compared using the standardised mean difference (SMD) with 95% confidence intervals (CIs). The heterogeneity of the included trials was evaluated through visual inspection of funnel plots and through the I2 statistic.
Results:
We identified seven trials with 326 participants with schizophrenia meeting the inclusion criteria. All these studies evaluated the overall clinical symptoms, and four of them evaluated overall cognitive functions. Sarcosine use achieved more significant effects than the use of its comparators in relieving overall clinical symptoms (SMD = 0.51, CI = 0.26–0.76, p < 0.01). Moreover, studies with the low Positive and Negative Syndrome Scale range of 70–79 showed significant effect size (ES)s of 0.67 (95% CI: 0.03–1.31, p = 0.04). In addition, trials enrolling patients with stable clinical symptoms had significant ESs: 0.53 (95% CI: 0.21–0.85, p < 0.01). Add-on sarcosine combined with first- and second-generation antipsychotics, except clozapine, had a positive effect. For overall cognitive functions, sarcosine showed a positive but insignificant effect compared with its comparators (SMD = 0.27, CI = −0.06 to 0.60, p = 0.10). The effects were correlated with increased female proportions and decreased illness duration, albeit nonsignificantly.
Conclusions:
The meta-analysis suggests that sarcosine may be associated with treatment effect on overall clinical symptoms in patients with schizophrenia but not cognitive functions.
AmiazRKentIRubinsteinK, et al. (2015) Safety, tolerability and pharmacokinetics of open label sarcosine added on to anti-psychotic treatment in schizophrenia - preliminary study. Isr J Psychiatry Relat Sci52: 12–15.
2.
AndreasenNC (1982) Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry39: 784–788.
3.
ArvanovVLLiangXSchwartzJ, et al. (1997) Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther283: 226–234.
4.
ArvanovVLWangRY (1999) Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine. J Pharmacol Exp Ther289: 1000–1006.
5.
BeesleySSullenbergerTPilliJ, et al. (2019) Colocalization of distinct NMDA receptor subtypes at excitatory synapses in the entorhinal cortex. J Neurophysiol121: 238–254.
6.
ChangCHLaneHYTsengPT, et al. (2019) Effect of N-methyl-D-aspartate-receptor-enhancing agents on cognition in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials. J Psychopharmacol33: 436–448.
7.
ChoiKHWykesTKurtzMM (2013) Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: Meta-analytical investigation of efficacy. Br J Psychiatry203: 172–178.
8.
CoyleJT (1996) The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry3: 241–253.
DalmauJGleichmanAJHughesEG, et al. (2008) Anti-NMDA-receptor encephalitis: Case series and analysis of the effects of antibodies. Lancet Neurol7: 1091–1098.
11.
FreedmanR (2003) Schizophrenia. N Engl J Med349: 1738–1749.
12.
FukuyamaKKatoRMurataM, et al. (2019) Clozapine normalizes a glutamatergic transmission abnormality induced by an impaired NMDA receptor in the thalamocortical pathway via the activation of a group III metabotropic glutamate receptor. Biomolecules9: pii: E234.
13.
GreenMFNuechterleinKHGoldJM, et al. (2004) Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry56: 301–307.
14.
GuoJYRaglandJDCarterCS (2019) Memory and cognition in schizophrenia. Mol Psychiatry24: 633–642.
15.
HallRC (1995) Global assessment of functioning. A modified scale. Psychosomatics36: 267–275.
16.
HerreroPContadorISternY, et al. (2019) Influence of cognitive reserve in schizophrenia: A systematic review. Neurosci Biobehav Rev108: 149–159.
17.
HollmannMHeinemannS (1994) Cloned glutamate receptors. Annu Rev Neurosci17: 31–108.
18.
IbrahimHMHoggAJJrHealyDJ, et al. (2000) Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am J Psychiatry157: 1811–1823.
19.
IwataYNakajimaSSuzukiT, et al. (2015) Effects of glutamate positive modulators on cognitive deficits in schizophrenia: A systematic review and meta-analysis of double-blind randomized controlled trials. Mol Psychiatry20: 1151–1160.
20.
JadadARMooreRACarrollD, et al. (1996) Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Control Clin Trials17: 1–12.
21.
JavittDCDuncanLBallaA, et al. (2005) Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: Implications for mechanisms of action. Mol Psychiatry10: 275–287.
22.
JavittDCLiedermanECienfuegosA, et al. (1999) Panmodal processing imprecision as a basis for dysfunction of transient memory storage systems in schizophrenia. Schizophr Bull25: 763–775.
23.
KaneJM (1992) Clinical efficacy of clozapine in treatment-refractory schizophrenia: An overview. Br J Psychiatry Suppl160: 41–45.
24.
KaySRFiszbeinAOplerLA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull13: 261–276.
25.
KrystaKMurawiecSKlasikA, et al. (2013) Sex-specific differences in cognitive functioning among schizophrenic patients. Psychiatr Danub25(Suppl 2): S244–S246.
26.
KrystalJHKarperLPSeibylJP, et al. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry51: 199–214.
27.
KubotaTJibikiIEnokidoF, et al. (2000) Effects of MK-801 on clozapine-induced potentiation of excitatory synaptic responses in the perforant path-dentate gyrus pathway in chronically prepared rabbits. Eur J Pharmacol395: 37–42.
28.
KumarVAhmadMANajmiAK, et al. (2016) Effect of sarcosine (a glycine transport 1 inhibitor) and risperidone (an atypical antipsychotic drug) on MK-801 induced learning and memory deficits in rats. Drug Res (Stuttg)66: 11–17.
29.
LaneHYChangYCLiuYC, et al. (2005) Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: A randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry62: 1196–1204.
30.
LaneHYHuangCLWuPL, et al. (2006) Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry60: 645–649.
31.
LaneHYLinCHHuangYJ, et al. (2010) A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol13: 451–460.
32.
LaneHYLiuYCHuangCL, et al. (2008) Sarcosine (N-methylglycine) treatment for acute schizophrenia: A randomized, double-blind study. Biol Psychiatry63: 9–12.
33.
LangeCDeutschenbaurLBorgwardtS, et al. (2017) Experimentally induced psychosocial stress in schizophrenia spectrum disorders: A systematic review. Schizophr Res182: 4–12.
34.
LiFTsienJZ (2009) Memory and the NMDA receptors. N Engl J Med361: 302–303.
35.
LiebermanJABymasterFPMeltzerHY, et al. (2008) Antipsychotic drugs: Comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev60: 358–403.
36.
LinCYLiangSYChangYC, et al. (2017) Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial. World J Biol Psychiatry18: 357–368.
37.
Lopez-CorcueraBMartinez-MazaRNunezE, et al. (1998) Differential properties of two stably expressed brain-specific glycine transporters. J Neurochem71: 2211–2219.
38.
MalhotraAKPinalsDAAdlerCM, et al. (1997) Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology17: 141–150.
39.
MalhotraAKPinalsDAWeingartnerH, et al. (1996) NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology14: 301–307.
40.
Manahan-VaughanDWildforsterVThomsenC. (2008) Rescue of hippocampal LTP and learning deficits in a rat model of psychosis by inhibition of glycine transporter-1 (GlyT1). Eur J Neurosci28: 1342–1350.
41.
Meador-WoodruffJHHealyDJ (2000) Glutamate receptor expression in schizophrenic brain. Brain Res Brain Res Rev31: 288–294.
42.
MoherDLiberatiATetzlaffJ, et al. (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J Clin Epidemiol62: 1006–1012.
43.
NakazawaKMcHughTJWilsonMA, et al. (2004) NMDA receptors, place cells and hippocampal spatial memory. Nat Rev Neurosci5: 361–372.
44.
NebieridzeNZhangXLChachuaT, et al. (2012) β-Estradiol unmasks metabotropic receptor-mediated metaplasticity of NMDA receptor transmission in the female rat dentate gyrus. Psychoneuroendocrinology37: 1845–1854.
45.
NimgaonkarVLPrasadKMChowdariKV, et al. (2017) The complement system: A gateway to gene-environment interactions in schizophrenia pathogenesis. Mol Psychiatry22: 1554–1561.
46.
OlneyJWFarberNB (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry52: 998–1007.
47.
PalysKEBergerVW (2013) A note on the Jadad score as an efficient tool for measuring trial quality. J Gastrointest Surg17: 1170–1171.
48.
PeyrovianBRosenblatJDPanZ, et al. (2019) The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry92: 387–404.
49.
PompiliMShrivastavaASerafiniG, et al. (2013) Bereavement after the suicide of a significant other. Indian J Psychiatry55: 256–263.
50.
SchwielerLEngbergGErhardtS (2004) Clozapine modulates midbrain dopamine neuron firing via interaction with the NMDA receptor complex. Synapse52: 114–122.
51.
SinghSPSinghV (2011) Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs25: 859–885.
52.
SnyderMAGaoWJ (2019) NMDA receptor hypofunction for schizophrenia revisited: Perspectives from epigenetic mechanisms. Schizophr Res. Epub ahead of print 9April2019. DOI: 10.1016/j.schres.2019.03.010.
53.
StrzeleckiDKaluzynskaOSzyburskaJ, et al. (2015a) No changes of cardiometabolic and body composition parameters after 6-month add-on treatment with sarcosine in patients with schizophrenia. Psychiatry Res230: 200–204.
54.
StrzeleckiDKaluzynskaOSzyburskaJ, et al. (2016a) MMP-9 serum levels in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study). Int J Mol Sci17: pii: E1075.
55.
StrzeleckiDKaluzynskaOWysokinskiA (2016b) BDNF serum levels in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study). Psychiatry Res242: 54–60.
56.
StrzeleckiDPodgorskiMKaluzynskaO, et al. (2015b) Supplementation of antipsychotic treatment with sarcosine - GlyT1 inhibitor - causes changes of glutamatergic 1NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia. Neurosci Lett606: 7–12.
57.
StrzeleckiDPodgorskiMKaluzynskaO, et al. (2015c) Supplementation of antipsychotic treatment with the amino acid sarcosine influences proton magnetic resonance spectroscopy parameters in left frontal white matter in patients with schizophrenia. Nutrients7: 8767–8782.
58.
StrzeleckiDPodgorskiMKaluzynskaO, et al. (2015d) Adding sarcosine to antipsychotic treatment in patients with stable schizophrenia changes the concentrations of neuronal and glial metabolites in the left dorsolateral prefrontal cortex. Int J Mol Sci16: 24475–24489.
59.
StrzeleckiDUrban-KowalczykMWysokinskiA (2018a) Serum levels of interleukin 6 in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study). Hum Psychopharmacol33: e2652.
60.
StrzeleckiDUrban-KowalczykMWysokinskiA (2018b) Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study). Psychiatry Res268: 447–453.
61.
ThebergeJWilliamsonKEAoyamaN, et al. (2007) Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br J Psychiatry191: 325–334.
62.
TsaiGLaneHYYangP, et al. (2004) Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry55: 452–456.
63.
TsaiGELinPY (2010) Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des16: 522–537.
64.
ZhangBHanMTanS, et al. (2017) Gender differences measured by the MATRICS consensus cognitive battery in chronic schizophrenia patients. Sci Rep7: 11821.
65.
ZhangHXHyrcKThioLL (2009) The glycine transport inhibitor sarcosine is an NMDA receptor co-agonist that differs from glycine. J Physiol587: 3207–3220.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
